Compare CVKD & EONR.WS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CVKD | EONR.WS |
|---|---|---|
| Founded | 2022 | N/A |
| Country | United States | |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Oil & Gas Production |
| Sector | Health Care | Energy |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.4M | 2.8M |
| IPO Year | 2022 | N/A |
| Metric | CVKD | EONR.WS |
|---|---|---|
| Price | $1.71 | $0.04 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $14.00 | N/A |
| AVG Volume (30 Days) | ★ 103.3K | 320.0 |
| Earning Date | 11-16-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 23.94 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.82 | $0.07 |
| 52 Week High | $12.50 | $0.07 |
| Indicator | CVKD | EONR.WS |
|---|---|---|
| Relative Strength Index (RSI) | 66.44 | N/A |
| Support Level | $0.88 | N/A |
| Resistance Level | $2.23 | N/A |
| Average True Range (ATR) | 0.21 | 0.00 |
| MACD | 0.07 | 0.00 |
| Stochastic Oscillator | 78.44 | 0.00 |
Cadrenal Therapeutics Inc is a late-stage biopharmaceutical company advancing novel therapies for life-threatening immune and thrombotic conditions. Its product candidate, CAD-1005, is a first-in-class selective 12-LOX inhibitor being developed to treat heparin-induced thrombocytopenia (HIT), a deadly immune-mediated thrombotic disorder. The pipeline includes two additional clinical-stage assets: tecarfarin and frunexian. Tecarfarin is an oral vitamin K antagonist (VKA) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients requiring chronic anticoagulation. Frunexian is a first-in-class, Phase 2-ready intravenous Factor XIa inhibitor designed for acute care settings where contact activation of coagulation by medical devices or artificial surfaces.